Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals ($INO), AstraZeneca's ($AZN) MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds. The Defense Advanced Research Projects Agency (DARPA) is paying for the project, through which the group will develop DNA-based antibodies for infectious diseases, focusing on the flu, Pseudomonas aeruginosa and Staphylococcus aureus. More

Read more on